These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 33015726)

  • 41. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.
    Ng CH; Lin SY; Chin YH; Lee MH; Syn N; Goh XL; Koh JH; Quek J; Hao Tan DJ; Mok SF; Tan E; Dan YY; Chew N; Khoo CM; Siddiqui MS; Muthiah M
    Endocr Pract; 2022 Feb; 28(2):223-230. PubMed ID: 34606980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
    Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
    Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I; Selph S
    Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
    Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
    Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
    Deng M; Wen Y; Yan J; Fan Y; Wang Z; Zhang R; Ren L; Ba Y; Wang H; Lu Q; Fan H
    BMC Med; 2023 Nov; 21(1):447. PubMed ID: 37974258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
    Bril F; Cusi K
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Srinonprasert V; Anothaisintawee T; Kongmalai P; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1182037. PubMed ID: 37441498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease.
    Manka PP; Kaya E; Canbay A; Syn WK
    Dig Dis Sci; 2021 Nov; 66(11):3676-3688. PubMed ID: 34410573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
    Vincent RK; Williams DM; Evans M
    Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
    Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
    Doycheva I; Loomba R
    Adv Ther; 2014 Jan; 31(1):30-43. PubMed ID: 24385405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
    Tsiampali C; Papaioannidou P; Goulas A; Polyzos SA
    Expert Rev Clin Pharmacol; 2023; 16(11):1063-1072. PubMed ID: 37864548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
    An J; Sohn JH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
    Cariou B
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.